ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Instil Bio, Inc. (NQ:TIL)

11.27 +0.27 (+2.45%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	66,440
Open	11.16
Bid (Size)	10.91 (100)
Ask (Size)	11.80 (400)
Prev. Close	11.00
Today's Range	10.90 - 11.60
52wk Range	10.17 - 42.79
Shares Outstanding	128,761,873
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

September 10, 2025

From Instil Bio

Via GlobeNewswire

Instil Bio Posts Wider Loss in Q2 ↗

August 13, 2025

Via The Motley Fool

Performance

YTD	N/A	N/A
1 Month	+4.5%	+4.5%
3 Month	-35.8%	-35.8%
6 Month	-59.0%	-59.0%
1 Year	-47.9%	-47.9%

More News

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025

From Instil Bio

Via GlobeNewswire

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

July 31, 2025

From Instil Bio

Via GlobeNewswire

Here are the top movers in Monday's session. ↗

July 07, 2025

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 02, 2025

Via Benzinga

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 02, 2025

From Instil Bio

Via GlobeNewswire

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025

From Instil Bio

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 02, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

June 02, 2025

Via Chartmill

These stocks that are showing activity before the opening bell on Monday. ↗

June 02, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 02, 2025

Via Benzinga

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

June 02, 2025

From Instil Bio

Via GlobeNewswire

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025

From Instil Bio

Via GlobeNewswire

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 23, 2025

From Instil Bio

Via GlobeNewswire

Keep an eye on the top gainers and losers in Thursday's session. ↗

May 22, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 22, 2025

Via Benzinga

These stocks are moving in today's session ↗

May 22, 2025

Via Chartmill

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated

May 22, 2025

From Instil Bio

Via GlobeNewswire

What's going on in today's pre-market session ↗

May 20, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 20, 2025

Via Benzinga

Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket ↗

May 20, 2025

Via Benzinga

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

From Instil Bio

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 25, 2025

Via Benzinga

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 04, 2025

From Instil Bio

Via GlobeNewswire

Frequently Asked Questions

Is Instil Bio, Inc. publicly traded?

Yes, Instil Bio, Inc. is publicly traded.

What exchange does Instil Bio, Inc. trade on?

Instil Bio, Inc. trades on the Nasdaq Stock Market

What is the ticker symbol for Instil Bio, Inc.?

The ticker symbol for Instil Bio, Inc. is TIL on the Nasdaq Stock Market

What is the current price of Instil Bio, Inc.?

The current price of Instil Bio, Inc. is 11.27

When was Instil Bio, Inc. last traded?

The last trade of Instil Bio, Inc. was at 01/02/26 04:00 PM ET

What is the market capitalization of Instil Bio, Inc.?

The market capitalization of Instil Bio, Inc. is 1.45B

How many shares of Instil Bio, Inc. are outstanding?

Instil Bio, Inc. has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.